Pharmaceuticals, Biotechnology and Life Sciences
Celyad has kicked off the SHRINK trial, a third clinical trial with its lead product candidate CYAD-01 (CAR-T NKG2D), targeting metastatic colorectal patients, the company said Thursday.
Ablynx and Sanofi have made a deal for research collaboration and global exclusive licensing agreement related to Nanobody-based therapeutics for the treatment of various immune-mediated inflammatory diseases.
Cellectis S.A. and Calyxt, Inc. announced on Thursday the pricing of Calyxt’s initial public offering of 7,000,000 shares of its common stock at the initial public offering price of $8.00 per share.
The U.S. Food and Drug Administration (FDA) has cleared Neovacs’s Investigational New Drug (IND) application for IFNalpha Kinoid in the treatment of dermatomyositis, which allows the Company to initiate in the US its Phase IIa clinical trial already on-going in European countries.
CPhI Korea returns to Seoul COEX Convention and Exhibition Centre for its fourth edition from 22nd-24th August 2017. The show will co-locate with ICSE, P-MEC, BioPh and Health Ingredients Korea. Reflecting the global interest in the South Korean pharma market, CPhI Korea 2017 will see a 13% rise in the number of exhibitors, in addition to a more than doubling of overseas buyers since 2015.
The U.S. Food and Drug Administration on Tuesday approved Gildad’s Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing two previously approved drugs – sofosbuvir and velpatasvir – and a new drug, voxilaprevir.
Novatris has reported net income of $2.9 million for the second quarter of 2017 which is a slight decrease comparing the same period last year.
The U.S. Food and Drug Administration has approved Puma Biotechnology’s neratinib for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.
Ablynx has announced that Hilde Windels will be nominated as an Independent Non-Executive Director at the Company`s forthcoming Special General Meeting of its shareholders to be held on 18 August 2017.
Novartis has confirmed positive 5 year efficacy and safety results for Cosentyx from a Phase III long-term extension study in patients with moderate-to-severe plaque psoriasis.